فاس نيوز ميديا جريدة الكترونية جهوية تعنى بشؤون و أخبار جهة فاس مكناس – متجددة على مدار الساعة
In a move aimed at alleviating the financial burden on patients, the Ministry of Health and Social Protection announced a reduction in the prices of 17 medications, including original (brand-name) drugs, generic equivalents, and biosimilars, following a review of their prices. This announcement was made in an official bulletin issued on February 10, 2025.
The published list in the official gazette includes medications for cancer treatment and other diseases, with the price reduction covering a wide range of therapies used in various medical fields. Among the medications that saw price reductions are:
- Afinitor, used in the treatment of tumors of pulmonary and gastrointestinal origin, saw its price drop from 16,280 dirhams to 11,832 dirhams.
- NEORAL, used in dermatological treatments, saw the price of its 100 mg capsules reduced from 1,728 dirhams to 1,705 dirhams, while the oral solution decreased from 1,622 dirhams to 1,549 dirhams.
- Nexavar 200 mg, commonly used in chemotherapy, saw its price drop from 18,759 dirhams to 10,700 dirhams.
- Pradaxa 110 mg, intended for the prevention of strokes and blood clots, saw the price of a box containing 60 tablets reduced from 1,026 dirhams to 733 dirhams, and a box containing 30 tablets decreased from 531 dirhams to 365 dirhams.
- Stivarga, used in the treatment of colorectal cancer, saw its price drop from 28,639 dirhams to 26,806 dirhams.
This step is part of the Ministry of Health’s efforts to improve access to essential medications and reduce the financial burden on patients, especially in light of the continuous rise in treatment costs. These measures are also part of the ministry’s policy to periodically review drug prices to ensure their availability at affordable rates.
This reduction is expected to have a positive impact on patients, allowing them to obtain necessary medications at lower prices, thereby improving quality of life and easing the financial burden on families.
The Ministry of Health will continue to monitor drug prices in the market to ensure that citizens benefit from these reductions, while emphasizing the importance of maintaining the quality of medications available in pharmacies.
